Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

King To End Agreement With Elan On Sonata Modified-Release Formulation

This article was originally published in The Pink Sheet Daily

Executive Summary

King is discontinuing efforts to develop a modified-release formulation of the insomnia agent Sonata (zaleplon)

You may also be interested in...



Sonata, Cardizem LA Paragraph IV Certifications Filed

Paragraph IV certification for Jones Pharma’s insomnia agent Sonata (zaleplon) filed June 21. New chemical exclusivity for the drug expired in 2004.

Sonata, Cardizem LA Paragraph IV Certifications Filed

Paragraph IV certification for Jones Pharma’s insomnia agent Sonata (zaleplon) filed June 21. New chemical exclusivity for the drug expired in 2004.

Altace Sales Declines Reflect King's Inventory Workdown Program

Wholesaler inventory reductions of the ACE inhibitor totaled $180 mil. in value in 2004, representing almost all of the 35% decline in Altace sales during the year. Wholesale inventory reductions for Altace and Sonata are continuing as King aims for an on-hand supply of 1.5 months.

Topics

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel